Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
4.060
-0.050 (-1.22%)
Nov 2, 2026, 2:59 PM EST - Market open
Oramed Pharmaceuticals Market Cap
Oramed Pharmaceuticals has a market cap or net worth of $168.89 million as of November 2, 2026. It is the 21,524th most valuable company in the world and the 3,696th biggest in the United States. Its market cap has increased by 72.33% in one year.
Market Cap
168.89M
Enterprise Value
97.14M
1-Year Change
72.33%
Global Rank
Country Rank
#3,696 United States
Category
ChartMarket Cap Chart
Since May 31, 2007, Oramed Pharmaceuticals's market cap has increased from $29.90M to $168.89M, an increase of 464.83%. That is a compound annual growth rate of 9.32%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 2, 2026 | 168.89M | 48.93% |
| Dec 31, 2025 | 113.40M | 16.19% |
| Dec 31, 2024 | 97.60M | 4.72% |
| Dec 29, 2023 | 93.20M | -80.20% |
| Dec 30, 2022 | 470.60M | -13.48% |
| Dec 31, 2021 | 543.90M | 441.73% |
| Dec 31, 2020 | 100.40M | 12.05% |
| Dec 31, 2019 | 89.60M | 71.98% |
| Dec 31, 2018 | 52.10M | -59.55% |
| Dec 29, 2017 | 128.80M | 58.62% |
| Dec 30, 2016 | 81.20M | -18.15% |
| Dec 31, 2015 | 99.20M | 115.18% |
| Dec 31, 2014 | 46.10M | -62.40% |
| Dec 31, 2013 | 122.60M | 330.18% |
| Dec 31, 2012 | 28.50M | 45.41% |
| Dec 30, 2011 | 19.60M | 11.36% |
| Dec 31, 2010 | 17.60M | -31.52% |
| Dec 31, 2009 | 25.70M | 16.82% |
| Dec 31, 2008 | 22.00M | 83.33% |
| Dec 31, 2007 | 12.00M | -59.87% |
| May 31, 2007 | 29.90M | - |
View and export this data all the way back to 2007. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Yarrow Bioscience | 185.16M |
| Whitehawk Therapeutics | 184.71M |
| Sionna Therapeutics | 174.97M |
| MediWound | 171.71M |
| Invivyd | 171.46M |
| AN2 Therapeutics | 170.95M |
| ALX Oncology Holdings | 168.70M |
| Adagene | 168.53M |